Compare III & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | III | MSLE |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Canada |
| Employees | 1500 | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.1M | 186.9M |
| IPO Year | 2006 | 2007 |
| Metric | III | MSLE |
|---|---|---|
| Price | $6.18 | $6.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.80 | ★ $24.17 |
| AVG Volume (30 Days) | ★ 222.1K | 64.2K |
| Earning Date | 11-02-2026 | 11-15-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 216.67 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $192,745,000.00 | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | $51.50 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $3.74 | $5.44 |
| 52 Week High | $6.45 | $13.39 |
| Indicator | III | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 32.08 |
| Support Level | $3.86 | $5.52 |
| Resistance Level | N/A | $10.58 |
| Average True Range (ATR) | 0.18 | 0.58 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 92.59 | 7.39 |
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.